Carbepenam resistance prevalence in north India: A retrospective analysis

Harpreet Singh; Phool Kanwar Singh Brar; Vikas Kumar; Shital Bhardwaj; Gulshan Dhawan

doi:10.53730/ijhs.v6nS2.7904

Carbepenam resistance prevalence in north India

A retrospective analysis

https://doi.org/10.53730/ijhs.v6nS2.7904

Authors

Harpreet Singh Assistant professor, Dept of Anaethesiology, Saraswati medical college, Unnao, U.P.
Phool Kanwar Singh Brar M.B.B.S, M.D, IDCCM, I.C.U. Director, Dept of Critical Care, Park Healing Touch Hospital, Ambala
Vikas Kumar
001vkv@gmail.com
Associate professor, Department of anesthesia, Adesh medical college and hospital, Kurukshetra Haryana
Shital Bhardwaj Consultant Gynaecologist, Pristyn care, Chandigarh.
Gulshan Dhawan Associate Professor, Dept of Anaethesiology, Adesh Medical College and Hospital, Kurukshetra, Haryana, India

Keywords:

carbepenam resistance prevalence, bacteremia, Indian intensive care

Abstract

Background: We investigated the clinical consequences of healthcare-associated bacteremia in light of rising antimicrobial resistance and limited therapy choices for carbapenem-resistant bacteremia. Methods: Between March 2020 and March 2022, a retrospective observational study of carbapenem-resistant Gram-negative bacteremia was conducted at a tertiary care hospital in North India. Results: Patients in our study spent an average of 11.76 days in the intensive care unit (ICU), with a mean time to bacteremia of 6.4 days following admission. Klebsiella pneumoniae was the most prevalent pathogen (44 percent). Patients receiving combination treatment had a reduced death rate (44.8%) than those receiving colistin monotherapy (66.6%) (P = 0.35). Conclusion: Carbapenem resistant bacteremia is a late-onset illness that affects patients who have been exposed to antibiotics in the ICU and has a 60 percent mortality rate after 30 days.

Downloads

Download data is not yet available.

References

Untreatable: Report by CDC details today's drug-resistant health threats.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.

Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: Treatment options with carbapenems compromised. J Assoc Physicians India. 2010;58:147–9.

Nair PK, Vaz MS. Prevalence of carbapenem resistant Enterobacteriaceae from a tertiary care hospital in Mumbai, India. J Microbiol Infect Dis. 2013;3:207–10.

Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in North India. Indian J Med Res. 2006;124:95–8.

Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. Clinical and Laboratory Standards Institute.

Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.

Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37:1463–9.

Parthasarathy P. Risk factors and mortality in carbapenem resistant gram negative bacteremias: A retrospective analysis from a tertiary health care setting in India. Poster Abstract 1608, ID Week. 2013

Ghafur A, Kannaian P, Tayade A. Clinical study of carbapenum-sensitive and carbapenem-resistant bacteraemia in neutropenic and non-neutropenic patients: The first series from India. Abstract P 1368, 23rd ECCMID. 2013

Published

25-05-2022

How to Cite

Singh, H., Brar, P. K. S., Kumar, V., Bhardwaj, S., & Dhawan, G. (2022). Carbepenam resistance prevalence in north India: A retrospective analysis. International Journal of Health Sciences, 6(S2), 10851–10857. https://doi.org/10.53730/ijhs.v6nS2.7904

Download Citation

Issue

Vol. 6 No. S2 (2022)

Section

Peer Review Articles

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.